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OBJECTIVES: In The Collaborative Atorvastatin Diabetes Study
(CARDS), atorvastatin 10mg reduced CHD (36%) and stroke
(48%) in primary CVD prevention patients in the UK with type
2 diabetes compared to placebo. However the transferability of
the clinical and economic beneﬁts for treatment algorithms and
populations beyond the UK are not known. Despite the fact that
relative risk reductions are similar between different populations,
baseline risk varies according to population. This study outlines
an approach to estimate baseline risk in a non-study diabetes
population and calculate cost-effectiveness therein using the trial
treatment effect. METHODS: A Markov model was developed
using the UKPDS risk function to model the incidence of CHD
and stroke assuming “no treatment”. The model allows re-
calibration of risk for non-study diabetes populations by substi-
tuting the UKPDS population, individual, and mean risk factors
with those of the population of interest. The treatment effect is
determined by multiplying estimated incidence rates by the
hazard ratio observed for CHD and stroke in CARDS. Compet-
ing hazards are used to estimate non-CV mortality. Model end-
points include event rates, estimated costs, survival and QALYs
gained associated with atorvastatin 10mg treatment. RESULTS:
Validity was tested by substituting the CARDS trial population
individual and mean risk factors with those from the UKPDS risk
function. The re-calibrated UKPDS risk function resulted in four-
year “no treatment” CHD predicted risk of 6.70% vs. actual risk
of 6.52% (97.4% of predicted value). The corresponding stroke
incidences were 2.37% and 2.48% (104.8% of predicted value).
CONCLUSION: This approach improves the external validity
by using the annual adjustment of baseline risk and maintains
the internal validity by using observed clinical trial treatment
effects. The re-calibrated model accurately predicted the inci-
dence rates observed in the CARDS trial and enhances general-
izability of clinical results to a non-study, non-UK population of
diabetes patients.
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CARDIOVASCULAR DISEASE—Patient Reported
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OBJECTIVE: For patients that suffered from an acute myocar-
dial infarct (AMI), the 2001 guidelines of the American Heart
Association (AHA) recommend indeﬁnite treatment with 1)
statins; 2) beta-blockers; 3) ace inhibitors or, if not tolerated,
angiotensin-receptor blockers; and 4) aspirin. This study inves-
tigates how the recommendations are followed by patients and
physicians as observed in pharmacy claims. METHODS: Retro-
spective, claims database study performed using data from a
large health insurer in the Mid-Atlantic region. Patients were
selected if they had an initial AMI episode (ICD-9 Code: 410. ¥
1) between January 1, 2002 and August 31, 2004. These patients
were then matched to their pharmacy claims between January 1,
2001 and December 31, 2004. For each patient, adherence is
deﬁned as the proportion of days covered. RESULTS: A total of
1958 patients were identiﬁed. The mean age was 60 years and
58% were male. Overall post-AMI adherence rates with recom-
mended therapy were as follows: 1) statins: 43%; 2) beta-
blockers: 45%; 3) ace-inhibitors or ARB’s: 36%. Requiring at
least 6 months (1 year, 2 years) of follow-up data post discharge,
adherence rates drop to 1) statins: 42% (40%, 35%); and 2)
beta-blockers: 43% (41%, 35%), ace-inhibitors or ARB’s: 35%
(33%, 29%). A total of 13% of patients can be deﬁned as adher-
ent to the AHA recommendations, ﬁlling more than 80% of all
recommended prescriptions, whereas 19% of patients have ﬁlled
zero of the recommended prescriptions. Notably, 12%-15% of
patients were receiving at least one of the drugs even before their
ﬁrst AMI. In this subgroup adherence rates decrease after the
AMI by 1) statins: 20%; and 2) beta-blockers: 22%, ace-
inhibitors or ARB’s: 30%. CONCLUSION: The AHA post-AMI
treatment recommendations are followed only by a minority of
patients. In addition, mean adherence rates drop after the AMI
if the patient was receiving prophylactic therapy.
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OBJECTIVE: To describe persistence patterns in the use of statin
therapy in a U.S. managed care population. METHODS: Three
years of pharmacy and eligibility claims data from a managed
care health plan with over two million members were utilized.
Patients with at least one paid statin prescription claim in 2002
were identiﬁed. Those with continuous eligibility for six-month
pre- and two-year post-index statin prescription and no statin
claims in a six-month washout period were included. Patients
with statin prescriptions ﬁlled at mail order pharmacies were
excluded. Individuals were followed for 2 years and proportion
of days covered (PDC) was calculated at 6, 12, 18, and 24
months to assess medication persistence. Days supplied for over-
lapping reﬁlls and last censored ﬁll were adjusted to account for
changes in statin therapy, early reﬁll, and days supplied beyond
the study period. RESULTS: A total of 14,047 patients met the
study criteria. Twenty percent were greater than 65 years of age,
56% were male, 20.5% had at least one diabetes-related pre-
scription, 63.5% had atorvastatin as index drug, and median age
was 55. Mean PDC at 6, 12, 18, and 24 months were 0.63, 0.54,
0.49, and 0.47 respectively. At 6 months, only 42.1% of the
study population remained adherent with their statin therapy,
with PDC of at least 80%. By 24-months, only 26% were adher-
ent. Patients taking diabetes related medications had higher
prevalence of adherence than their non-diabetic counterparts
after 6 months and this trend continued for all subsequent time
intervals over two years (p < 0.002). CONCLUSIONS: Adher-
ence rate of statin therapy remains suboptimal in this managed
care population. Programs to maintain patients on statin therapy
are essential to improve health outcomes and reduce drug
wastage costs due to therapy non-compliance.
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OUTPATIENT DISCONTINUATION AND RESTARTING OF
POST-MYOCARDIAL INFARCTION BETA-BLOCKER THERAPY
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OBJECTIVE: To estimate the one-year cumulative incidence of
discontinuation of post-MI beta-blocker therapy after hospital
discharge and the one-year cumulative incidence of restarting
therapy following discontinuation. METHODS: We conducted
a retrospective, population-based, inception cohort study among
all enrollees (n = 1334) of Group Health Cooperative (GHC, a
health maintenance organization) aged 30–79 years who sur-
vived a ﬁrst hospitalized MI during 1986–1996 (mean follow up
1.4 years) and were discharged from the hospital on beta-blocker
therapy. Using the GHC computerized pharmacy database, we
calculated the duration of therapy by assuming subjects were on
average 80% compliant with each beta-blocker prescription ﬁll.
We considered subjects to have discontinued therapy on the 60th
consecutive day they were without medication and to have
restarted therapy on the ﬁrst day they obtained a prescription ﬁll
following discontinuation. In sensitivity analyses, we varied
when we considered subjects to have discontinued therapy (i.e.,
on the 30th and the 90th consecutive day without medication).
We estimated the cumulative incidence using failure time analy-
ses. RESULTS: By one year post-discharge, 511 subjects discon-
tinued therapy; the cumulative incidence of discontinuation was
39.0% (95% CI: 36.3, 41.6). The cumulative incidence increased
to 50.7% (95% CI: 47.9, 53.3) and decreased to 33.4% (95%
CI: 30.9, 36.0) when our discontinuation deﬁnition required 30
and 90 days without medication, respectively. By one year post-
discontinuation, the cumulative incidence of restarting was
42.7% (95% CI: 39.1, 46.2). The cumulative incidence of
restarting increased to 52.9% (95% CI: 49.6, 56.1) and
decreased to 32.0% (95% CI: 28.4, 35.6) when our discontinu-
ation deﬁnition required 30 and 90 days without medication,
respectively. CONCLUSIONS: Our results indicate that patients
are likely to restart post-MI beta-blocker therapy after having
discontinued it. Studies considering only time to ﬁrst discontin-
uation may be oversimplifying the long-term utilization patterns
of therapy by misclassifying patients who subsequently restart.
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MEDICATION ADHERENCE: PREDICTORS AND IMPACT ON
HOSPITALIZATION RISK
Agarwal S, Hansen JE
Wolters Kluwer Health, Phoenix, AZ, USA
OBJECTIVES: The objectives of this study were to investigate
factors associated with adherence to medications for diabetes
and hyperlipidemia, and to assess the impact of adherence on
hospitalization risk. METHODS: Administrative claims and
cash prescriptions data from Wolters Kluwer Health’s IHR data-
base were utilized. This extensive database provides longitudinal
prescription history on about 157 million patients, prescription
and physician services’ history on about 35 million, and pre-
scription, physician services’ and hospitalization history on
about 6 million patients. Adult patients initiating therapy for
either condition between July 2003 and June 2004 and having
claims activity in the 12 months period prior to and following
the index prescription were identiﬁed. A Medication Possession
Ratio °Y´ 80% was considered to be indicative of adherence.
Hospitalization risk was deﬁned as the probability of being
admitted to a hospital in post-index period. Logistic regression
was employed to identify predictors of adherence including: age,
gender, payer type, charlson index, chronic disease score, pres-
ence of disease conditions and pill burden. Relationship between
hospitalization risk and adherence was also modeled using logis-
tic regression after adjusting for the same covariates described
previously. RESULTS: About 48.4% of the 116,607 diabetes
patients and 38.5% of the 285,853 hyperlipidemia patients were
adherent. Predictors of improved adherence in both disease
groups were male gender, being a Medicaid beneﬁciary, a higher
chronic disease score and lower pill burden. Comorbid diseases
including AMI, CAD, CHF, stroke and hyperlipidemia were
associated with higher adherence in the diabetes group. For both
disease conditions, hospitalization risk was signiﬁcantly higher
in non-adherent patients [Diabetes OR: 1.47 (p < 0.0001),
Hyperlipidemia OR: 1.24 (p < 0.0001)]. CONCLUSIONS:
Adherence to therapy is suboptimal for diabetes and hyperlipi-
demia, two chronic diseases that are major drivers of health care
spending. Furthermore, non-adherent patients faced a signiﬁ-
cantly higher risk of hospitalization compared to adherent
patients.
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STATIN NONCOMPLIANCE AFTER CHD HOSPITALIZATION
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OBJECTIVES: Examine the relationship of statin noncompli-
ance to subsequent hospitalization among new statin users after
coronary heart disease (CHD) hospitalization. METHODS:
Medstat Marketscan 1999–2002 databases including inpatient,
outpatient and pharmacy claims were utilized for this study. The
ﬁrst statin prescription ﬁll date within six months of CHD hos-
pitalization was identiﬁed as the index date. The sample con-
sisted of adults who had no statin use during the year prior to
the CHD hospitalization and had at least 2-years continuous
